Evidence map›Paper›PMID 39790835›Full record

ArticleRSC advances2025

Retraction: Iso-pencillixanthone A from a marine-derived fungus reverses multidrug resistance in cervical cancer cells through down-regulating P-gp and re-activating apoptosis.

Li Chen, Xinxin Li, Miaomiao Cheng, Siyuan Wang, Qiuhong Zheng, Qinying Liu

Abstract readRetraction Notice
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Li ChenInstitute of Biomedical and Pharmaceutical Technology, Fuzhou University Fuzhou 350002 P. R. China.
Xinxin LiInstitute of Biomedical and Pharmaceutical Technology, Fuzhou University Fuzhou 350002 P. R. China.
Miaomiao ChengInstitute of Biomedical and Pharmaceutical Technology, Fuzhou University Fuzhou 350002 P. R. China.
Siyuan WangInstitute of Biomedical and Pharmaceutical Technology, Fuzhou University Fuzhou 350002 P. R. China.
Qiuhong ZhengFujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital Fuzhou 350014 P. R. China zqh2858@foxmail.com liuqy@fjmu.edu.cn +86-591-8366-0063.
Qinying LiuFujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital Fuzhou 350014 P. R. China zqh2858@foxmail.com liuqy@fjmu.edu.cn +86-591-8366-0063.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This retracts the article DOI: 10.1039/C8RA09506J.].

Identifiers

PMID39790835
PMCPMC11715665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.